LONDON, Nov. 27, 2014 /PRNewswire/ -- INTRODUCTION
Prefilled syringes are gaining strong acceptance in the market as drug delivery systems for injectable drugs. They have become a preferred device for parenteral administration of drugs, mainly used for treatment of chronic conditions requiring patients to self-administer medication several times a week.
The origins of these syringes can be traced back to early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced syringes as drug delivery devices for heparins in Europe. Prefilled syringes were introduced initially as just a niche market product and their applications were limited to a few vaccines and anticoagulant products. Now they have been around for more than two decades and are used in all major therapeutic classes for injectable drug formulations. Owing to their numerous benefits over conventional delivery systems, prefilled syringes have become indispensable in the medical field. This is evident from our research during which we identified a large number of instances where prefilled syringes are being used to administer vaccines, anticoagulants, multiple sclerosis drugs, anti-arthritic drugs, anti-anaemic drugs and drugs from other classes. In addition, prefilled diluent syringes and flush syringes are also increasingly finding wider adoption. With pharma companies viewing prefilled syringes as a potent life cycle management tool, the pipeline is rich and growing rapidly.
The rising demand has also driven the manufacturers to introduce improvements in technology related to the material of prefilled syringes and lubrication (to reduce leachables and extractables). These developments will aid an increasing number of biologic drugs to reach the market. Additionally, the companies have developed multi-chamber prefilled syringes for use with lyophilised drugs. In our research, we have looked at how these developments and other factors are shaping the market and discussed the factors creating opportunities for various stakeholders in the market.
SCOPE OF THE REPORT
The 'Prefilled Syringes Market' report provides a comprehensive analysis of the state of prefilled syringes market. Starting with the basic introduction to prefilled syringes, their origin, components, and manufacturing material, this report talks about needlestick injuries and looks at the safety laws and legislations across major regional markets for injectable delivery. A key objective of the report is to enumerate various prefilled syringe systems available in the market, drugs available in these syringes and the corresponding market potential across different geographical regions. We have discussed various historical / likely future trends which have shaped / will shape the US, European, Japanese, Chinese and Rest of the World markets (such as India and Indonesia). We have also included a brief overview of biologics and biosimilars, one of the primary growth drivers of this market.
The study focuses on analysing the existing market size and potential future growth of these drug delivery devices across different drug therapeutic classes and regions. The forecast, over the next ten years, has been presented both in terms of volume (number of units) and value (USD billion). It takes into account the likely price variation which will occur as a result of mass adoption and increased competition. Owing to uncertainty surrounding the adoption of prefilled syringes in newer drug classes (which are currently in pipeline), we have done a multi-variate sensitivity analysis to understand the range of market growth scenarios.
In an effort to identify existing gaps and future opportunities, we have discussed the leading global prefilled syringe manufacturers in the industry, analysed their product portfolio and the likely future developments driven by these companies. We have also put emphasis and provided details on local manufacturers which are very well positioned to take advantage of the emerging home consumer markets.
The market forecasts across different segments and regions have been presented till 2024. 2013 is the base year; actual figures have been sourced and analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.
1. The global prefilled syringes market is likely to grow at a compounded annual growth rate (CAGR) of 11.3% between 2013 to 2024. By 2024, we expect the market to achieve sales of around 12.4 billion prefilled syringes.
2. Vaccines, diluent and flush syringes are likely to be some of the key growth areas. The emergence of biologics will be a major growth driver; growth in the long-term will be fuelled by pipeline drugs and the rising adoption in developing markets.
3. Increasing number of suppliers now provide ready to fill/ sterile prefilled syringes, which make up more than 80% of the prefilled syringes market. The integration of prefilled syringes with advanced delivery systems such as pen and autoinjectors will aid in gaining wider adoption.
4. Developed markets of the US and EU together accounted for 80% of the prefilled syringes market in 2013. With the increasing adoption in China and rest of the world markets, this domination is likely to decline; by 2024, we expect the share of US and EU markets to slip to ~60%.
5. The market is highly consolidated and is currently dominated by key global players such as Becton Dickinson, Gerresheimer, MGlas AG, SCHOTT and Nuova Ompi. Other companies, which are relatively new entrants (e.g. West Pharmaceutical Services, Unilife and Vetter Pharma) are likely to foster more innovation.
6. Many regional players, especially in China, Japan and other Asian economies, have also recently surfaced to exploit the opportunity offered by large home consumer markets.
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts' opinion reports
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of prefilled syringes market.
Chapter 3 provides a general overview of prefilled syringes including their origin, components, types, and manufacturing material. We have also listed the major prefilled syringes available and presented a high level market landscape.
Chapter 4 highlights the key growth drivers of prefilled syringes market. These include the growing trend of self-injection, rise in chronic diseases, changing patient demographics and growth of biologics. The chapter also talks about needlestick injuries and various preventive laws worldwide which have put the focus on safety features in prefilled syringes.
Chapter 5 highlights the leading therapeutic drug classes available in prefilled syringes. Also provided is a list of top ten drugs in prefilled syringes with three case studies. For each therapeutic class, we have identified the drugs available in prefilled syringes and estimated patent expiry; we have also looked at the biosimilars currently in development.
Chapter 6 details the technological developments in prefilled syringes market focusing on syringes being manufactured for lyophilised drugs.
Chapter 7 provides profiles of the key manufacturers of prefilled syringes. Each company profile includes information on financial performance, geographical presence, marketed devices, role and strategy for manufactured devices and recent developments.
Chapter 8 highlights the regional prefilled syringe manufacturers; we have briefly profiled the key players in Chinese, Japanese and Indian markets.
Chapter 9 provides the SWOT analysis of prefilled syringes market giving strategic insights in to the major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that can negatively impact the growth.
Chapter 10 analyses the regional markets (the US, Europe, Japan, China and RoW) for prefilled syringes. Within each region, the chapter focuses on the market size and various technological, commercial and regulatory details
Chapter 11 provides a detailed description of the likely evolution of prefilled syringes market. We have adopted a 'bottom-up' approach to identify the likely size of the market, both in terms of volume (number of units, in billions) and value (in USD billion).
Chapter 12 is a collection of interview transcripts. For the purposes of our study, we contacted a number of stakeholders in order to ascertain the key strategic initiatives and future roadmap of the industry.
Chapter 13 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 15 is an appendix, which provides a list of companies and organisations mentioned in this report.
Download the full report: https://www.reportbuyer.com/product/2243611/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/prefilled-syringes-market-2nd-edition-2014-2024-300002098.html